

- 42 Breathnach SM, Carrington P, Black MM. Neutrophil leukocyte migration in psoriasis vulgaris. *J Invest Dermatol* 1981;76:271-4.
- 43 Lazarus GS, Yost FJ, Thomas CA. Polymorphonuclear leukocytes: possible mechanism of accumulation in psoriasis. *Science* 1977;198:1162-3.
- 44 Dubertret L, Bertaux B, Fosse M, Touraine R. Psoriasis: a defect in the regulation of epidermal proteases, as shown by serial biopsies after cantharidin application. *Br J Dermatol* 1984;110:405-10.
- 45 Baker BS, Swain AF, Valdimarsson H, Fry L. T-cell subpopulations in the blood and the skin of patients with psoriasis. *Br J Dermatol* 1984;110:37-44.
- 46 Guilhou JJ, Clot J. Cellular immunity in psoriasis. *Acta Derm Venereol (Stockh)* 1984;(suppl 113):25-8.
- 47 Geerdink JPM. Immunology. In: Mier PD, van de Kerkhof PCM, eds. *Textbook of psoriasis*. Edinburgh: Churchill Livingstone, 1986:150-64.
- 48 Baker BS, Griffiths CEM, Lambert S, et al. The effects of cyclosporin A on T lymphocyte and dendritic cell subpopulations in psoriasis. *Br J Dermatol* 1987;116:503-10.

What every doctor needs to know about 11 November

From 11 November, with only a few exceptions, patients will have the right to see computer records that doctors or others may hold on them. The Data Protection Act, which has been introduced in stages, will become fully operational on that day, and the Data Protection Registrar will have powers to enforce compliance. "Data subjects" (patients) will have the right, after making a written request and paying a fee of not more than £10, to be told by the registered "data user" (a doctor, practice, or health authority with computer records) whether any personal information about them is held on computer files; they then have the right to be supplied with a copy of that information within 40 days. Before 11 November Parliament is to be asked to approve an order that will enable doctors to prevent access being given to information they consider "likely to cause serious harm" to the physical or mental health of the patient or another person.

What are the implications for doctors? Firstly, they will need to think more carefully about what is entered into computer files. Secondly, those who recorded personal health data on disc or tape before the idea of patients having a right to see their records was contemplated should consider reviewing and editing such records before 11 November. No such action is necessary with records held solely for research as these are exempt from access rights; and information held solely for word processing falls outside the act. Thirdly, doctors identified as having overall clinical responsibility for the patient who is seeking access to records will be asked by whoever is acting as data protection coordinator to scrutinise within a week or so the applicant's computer record and manual case notes to decide whether any data in the computer record need to be withheld or made more understandable. These doctors will usually need to consult with the other people who have contributed substantially to the patient's record. On the rare occasions when modified access is considered essential the doctor must indicate exactly what part of the computer record should be withheld and why. He should also decide whether the patient should be counselled about the record when it is made available.

How much extra work this will mean is not known. There may well be an initial surge of requests stimulated by the media and the freedom of information lobby. Subsequently requests may correlate with litigation and the numbers of patients under psychiatric care. Distrust of computers may lead some patients to request access, but generally such requests should be viewed as reflecting a breakdown in the mutual trust that should exist between patient and doctor.

Time spent fostering this relationship may reduce the time spent in dealing with requests to see records.

Those who want to know more should consult the excellent booklets explaining the legislation in practical terms that are available free from the Office of the Data Protection Registrar¹⁻⁸; and specific guidance on how requests for access to personal health data should be handled has recently been issued by the Department of Health and Social Security.⁹ At least those who are to function as data protection coordinators should now be familiar with these documents.

In the future the illogicality of treating computer held medical records differently from manual records will undoubtedly lead to pleas for patients to be granted rights of access to their whole medical record. Such a policy of openness was recommended by the Steering Group on Health Services Information,¹⁰ but the practical difficulties of implementing it are formidable.

FREDERICK V FLYNN

Professor of Chemical Pathology,
University College Hospital,
London WC1E 6AU

- 1 Data Protection Registrar. *Data Protection Act 1984. Guideline 1: introduction to the Act*. Wilmslow, Cheshire: Office of the Data Protection Registrar, 1987.
- 2 Data Protection Registrar. *Data Protection Act 1984. Guideline 2: the definitions*. Wilmslow, Cheshire: Office of the Data Protection Registrar, 1987.
- 3 Data Protection Registrar. *Data Protection Act 1984. Guideline 3: the registrar and registration*. Wilmslow, Cheshire: Office of the Data Protection Registrar, 1987.
- 4 Data Protection Registrar. *Data Protection Act 1984. Guideline 4: the data protection principles*. Wilmslow, Cheshire: Office of the Data Protection Registrar, 1987.
- 5 Data Protection Registrar. *Data Protection Act 1984. Guideline 5: individual's rights*. Wilmslow, Cheshire: Office of the Data Protection Registrar, 1987.
- 6 Data Protection Registrar. *Data Protection Act 1984. Guideline 6: the exemptions*. Wilmslow, Cheshire: Office of the Data Protection Registrar, 1987.
- 7 Data Protection Registrar. *Data Protection Act 1984. Guideline 7: enforcement and appeals*. Wilmslow, Cheshire: Office of the Data Protection Registrar, 1987.
- 8 Data Protection Registrar. *Data Protection Act 1984. Guideline 8: summary for computer bureaux*. Wilmslow, Cheshire: Office of the Data Protection Registrar, 1987.
- 9 Department of Health and Social Security. *Data Protection Act 1984: modified access to personal health information*. London: Department of Health and Social Security, 1987. (HC(87)14.)
- 10 Steering Group on Health Services Information. *A report from the confidentiality working group*. London: Department of Health and Social Security, 1984.

Should bronchodilators be combined in chronic bronchitis and emphysema?

There is a new enthusiasm for combining oral theophyllines with inhaled β_2 agonists to achieve better bronchodilatation in patients with chronic obstructive airways disease. Ipratropium bromide and high dose topical steroids may even be added. We need to consider carefully the value of this moderately expensive polypharmacy.

Theophylline has been used for many years, but how it achieves bronchodilatation remains unclear. Earlier notions of phosphodiesterase inhibition appear unlikely,^{1,2} at least at therapeutic plasma concentrations of 10-20 mg/l, and so do intracellular calcium translocation³ or antagonism of either adenosine receptor receptors⁴ or prostaglandins.⁵ In patients with asthma oral theophylline may potentiate the bronchodilatation from an inhaled β_2 agonist without increasing muscle tremor.⁶ A similar useful interaction has now been shown in patients with chronic bronchitis who show some bronchodilatation from salbutamol alone.⁷ In some (but not all) such patients bronchodilatation may be increased by adding ipratropium bromide to an inhaled β_2 agonist.⁸ This